Patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis showed significant up-regulation of protease-activated receptor 2, accompanied by increasing de novo lipogenesis, and leading to the dysfunction of cholesterol metabolism [30]. Here, F2RL1 is linked to metabolic dysfunction-associated steatotic liver disease.